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ABSTRACT
Objectives: In Indian health-care system with delayed access to a minimum number of catheter laboratories and rarity of insurance benefits, pre-
hospital and in-hospital thrombolytic has become the choice for patients with acute coronary syndrome (ACS), where many patients bear the economic 
burden of pharmacological thrombolytic. The present study was carried out to evaluate the pattern of prescribing of pharmacological thrombolytic 
agents in hospitalized ACS patients and associated cost burden.
Methods: A prospective observational cohort study of prescription was conducted for in-patient admitted to intensive care unit for thrombolytic and 
antithrombotic drug utilization pattern. The direct cost analysis was performed from patient’s perspective where a direct cost was calculated using 
pharmacy bills. All other cost was assumed to be same.
Results: Data of 288 patients were collected from which 108 (37.5%) patients were ST-elevation myocardial infarction (STEMI) and 180 (62.5%) 
patients were non-STEMI. The mean number of drugs prescribed was 11±2 which constitutes a mean of 3.1±0.7 reperfusion drugs. 59% of patients 
were prescribed with enoxaparin (0.6 ml/seconds route) for the mean duration of 4 days. The average prescription cost for ACS admission was around 
Rs.7159.5±5137.2 (Rs.1101-Rs.22202). The average cost of pharmacological thrombolytic therapy was Rs.4557±3468.3 (Rs. 23-Rs.12542). The mean 
cost of pharmacological thrombolytic therapy was found to be 63% of the total direct cost of drugs borne by the patient. The cost of therapy was 
positively correlated with duration of stay (p=0.000) and insignificantly correlated with a number of drugs.
Conclusion: Antiplatelets were the most preferred followed by anticoagulants. The mean number of drugs per encounter was high but was rational 
as per standard guidelines. The mean cost for pharmacological reperfusion therapy was found to be more than half of mean prescription cost for the 
management of ACS.
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INTRODUCTION
Cardiovascular diseases (CVDs)-related deaths in 2002 were more in 
India compared to other countries of the world. 52% of CVD in India 
occur below the age of 50 years and about 25% of acute myocardial 
infarction (AMI) in India occur below the age of 40 years. Disability-
adjusted life years lost due to CAD per 1000 populations in India are 
three times higher than in developed countries, thus having sustainable 
implication on Indian growing workforce [1-4]. Rates of primary 
percutaneous coronary intervention (PCI) were lower while that of 
thrombolytic treatment was higher than in developed countries. This 
is probably because three-fourth of the patients in India have to pay 
directly for their own treatment. The rates of coronary artery bypass 
graft were even lower in Indian patients. The reasons for poor invasive 
cardiac procedures are numerous and evident [1]. In Indian condition 
with delayed access to a minimum number of catheter laboratories 
and insurance benefits being a rarity, pre-hospital and in-hospital 
fibrinolytics have become the choice for patients with acute coronary 
syndrome (ACS) presenting early; however, adjunct antithrombotic 
agents and antiplatelet drugs maximize and maintain the drug 
dissolving effects and PCI [1].
The absolute pharmacoinvasive goal of ST-elevation myocardial 
infarction (STEMI) is to achieve earliest possible reperfusion. Several 
agents such as fibrinolytic, thrombolytic, and antiplatelet agents are 
proved to be beneficial in acute treatment phase. Various combinations 
of fibrinolytics and antithrombotics are practiced for the management 
of STEMI and non-NSTEMI. There are many literatures on cost-effective 
comparisons done between various reperfusion agents performed in 
developed countries [5]. There is hardly any outcome analysis done to 
assess the cost burden of reperfusion, antithrombotic, and antiplatelet 
drugs strategies for management of ACS in developing countries.
Our study focuses on the pattern of thrombolytic and antithrombotic 
therapy initiated in STEMI and NSTEMI and cost implications due to 
various thrombolytic strategies. This will help us to suggest intervention 
strategies to reduce the cost burden on patients.
METHODS
A prospective observational cohort study was carried out in intensive 
care unit (ICU) of a tertiary teaching hospital after obtaining approval 
from the Institutional Ethics Committee. Study was carried out over a 
period of 9 months from September 2014 to August 2015. In-patients 
with complaints of chest pain, breathlessness, palpitation, and sweating 
(either anyone with chest pain) were enrolled in the study. Patient 
population included both STEMI and NSTEMI which was confirmed 
after doing electrocardiogram.
Demographic data were recorded on the case record form. Patients’ 
clinical data including diagnosis, detailed history of illness, past history, 
and family history were noted. Information on drugs prescribed and 
administered was obtained from the patient’s chart. The date started 
and discontinued, the route of administration, and the quantity were 
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entered for each distinct drug. Cost analysis was performed from 
patient’s perspective. The cost of the drug was defined as the acquisition 
cost to the patient by the retail pharmacy within the hospital campus. 
Direct cost of pharmacological treatment was calculated using patient’s 
pharmacy bills. In each case, the price was calculated finally on a per 
unit basis for the strength and form actually used and then multiplied 
by a number of units actually administered to determine the cost of 
each drug received by a patient. Cost figures were assembled for each 
drug received by a patient, for all drugs received during an admission, 
and for all drugs prescribed in hospitals. Finally, total cost for all drugs 
received by the patients during 12 months period was calculated.
Statistical analysis used
The standard descriptive statistics were used, and all the collected 
data were analyzed using Microsoft Excel spreadsheet and interpreted. 
The results were evaluated against the set criteria and thresholds and 
presented in tables and figures. The data were represented as mean, 
numbers, or percentages. Pearson’s coefficient used to correlate 
between a number of drugs, stay in days, and cost of therapy. p<0.05 
was considered statistically significant.
RESULTS
A total of 288 patients were included with the first diagnosis of AMI over 
duration of 12 months from which 108 (37.5%) patients were STEMI 
and 180 (62.5%) patients were NSTEMI. Mean age of patients was 
59±9 years. Most of the patients were male, i.e., 189 (65.62%). Majority 
of the patients belong to the age group of 40-60 years (n=144) which 
comprised about 50% of total patients (Table 1). Hypertension and 
type II diabetes mellitus constituted majorly as comorbid conditions 
in the age group of 61-80 years (n=81) (Fig. 1). Most of the patients 
presented with chest pain (n=279) and breathlessness (n=117). Mean 
stay in ICU was 6±4 days.
A total of 3201 drugs were prescribed in 288 patients. Mean number 
of drugs prescribed per patients was 11. Antiplatelet drugs were 
most frequently prescribed drugs in 92.5% of the patients. Aspirin 
270 (93.75%) was most frequently prescribed drug followed by 
clopidogrel 261 (90.62%). Low molecular weight heparin (LMWH) 
preferably, enoxaparin and unfractionated heparin (UFH) were equally 
practiced as anticoagulants either alone or together (administered on 
a different day) in each of the 171 (59%) patients. Streptokinase was 
used as initial fibrinolytic agent only limited to 108 (37.5%) patients 
(Table 2).
The other class of drugs prescribed was antihyperlipidemia 
(atorvastatin) and antiemetic (ondansetron) in 90.62%. Pantoprazole 
was prescribed in 87% patients. A total of 180 (62.5%) antimicrobial 
drugs were used among which commonly prescribed was ceftriaxone 
(31.25%).
Mean total cost of pharmacotherapy per patient was Rs. 7159.5±5137.2 
among which the mean cost for thrombolytic and antithrombotic 
therapy was Rs. 4557±3468.3 (Fig. 2). Average number of drugs per 
patient was found to be 11±2. Duration of ICU stay was not positively 
correlated with number of drugs (Pearson’s correlation r=0.31, 
p=0.08). Cost of therapy was positively correlated with duration of stay 
(Pearson’s correlation r=0.59, p=0.000) and not positively correlated 
with number of drugs (Pearson’s correlation r=0.27, p=0.12).
DISCUSSION
The study was carried out with the aim to estimate the cost incurred 
for pharmacological thrombolytic and antithrombotic therapy during 
a hospital stay in ACS patients and to identify the indicators that 
decline the cost of the same. The mean age of patients in our study was 
slightly lower when compared to a study that reported 60.45±12.45 
and 64 years [6]. The majority of the patients in our study were male 
which is comparable to earlier Indian and foreign studies [7,8]. In our 
study, prevalence of hypertension and type 2 diabetes is generally 50%. 
However, in our study, the prevalence of these comorbid conditions 
was lower than in Indian study performed [9]. A pattern of comorbid 
condition varies within study population. Mean stay in ICU was higher 
Table 1: Demographic details of AMI in‑patients
Age/sex distribution of patient with AMI




Length of stay during first admission





Number of drugs administered to patient during first admission






Route of administration Number of drugs (%)
By mouth 540 (61.22)
Intravenous 162 (18.36)
Subcutaneous 180 (20.40)
AMI: Acute myocardial infarction
Fig. 1: Percentage distribution of co‑morbidities in various age 
groups
Fig. 2: Average cost of pharmacological reperfusion and 
thrombolytic from total cost
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compared with other studies [10,11]. The possible reasons may be 
due to difference in practice policies in different hospitals. Duration of 
ICU stay was not positively correlated with a number of drugs which 
contradicts the known fact [12], possibly due to the management 
strategy followed in ACS.
In an Indian study [13], mean number of drugs was more than 10, 
which was also observed in our study but was in contrast to a study 
that reported prescribing of <10 drugs per patient [6]. This difference 
can be due to difference in morbidity pattern and different prescribing 
practices in different countries. As per ACC/AHA guidelines, there 
are three classes of recommendations. Class 1 drugs are those having 
highest benefit–risk ratio and recommended. Class 2 drugs are 
those with somewhat less benefit–risk ratio compared with class 1 
and are probably recommended. Class 3 drugs are those that are 
not recommended or potentially harmful. In our study considering 
rationality based on ACC/AHA guidelines for ACS in all NSTEMI 
patients, guidelines were adhered to. As far as drug therapy for STEMI 
is concerned, majority of prescriptions adhered to the guidelines 
in the form of Classes 1 and 2 recommendations. The use of aspirin, 
clopidogrel, UFH, LMWH, and fibrinolytics was used as clot dissolving 
and prevention cocktail strategies according to standard ACC/AHA 
guidelines [14].
Antiplatelet drugs were most frequently prescribed, it was found to 
similar and comparable to other studies [15]. Aspirin and clopidogrel 
were mostly preferred for inhibition of blood clots in coronary artery 
and peripheral vessels in majority of the patients. In our study, none 
of the patients received GP III/IIa receptor antagonist as none of 
our patients underwent primary PCI. Only one-third of the patients 
received fibrinolytics depending on their early presentation, and more 
than 50% were prescribed with enoxaparin and UFH. Streptokinase 
was not commonly used agent compared to LMWH and UFH though it 
is the least expensive option available. This is due to questionable effect 
on late presentation to hospital and possible adverse effects [16]. Other 
studies had a higher use of thrombolytics as compared to our study in 
suspected ACS [17-19]. UFH alone has been used for anticoagulation in 
the majority of patients after undergoing fibrinolysis (streptokinase). 
Even LMWH has been preferred alone as well as after fibrinolysis in 
STEMI patients. More than one-third of the patients were prescribed 
initially with UFH and then switched to LMWH after 1-2 days. This 
strategy is probably used because of half-life of UFH is 30-60 minutes 
as compared to enoxaparin having half-life of 4-6 hrs [20]. Switching 
strategy is preferred as many evidence suggest LMWH as an effective 
alternative antithrombotic therapy to UFH because of its favorable 
pharmacokinetic profile and clinical advantages [15,21,22]. In our 
study, LMWH has been used in more than 60% of patients because of 
its safety profile compared to UFH. Warfarin is least preferred among 
all the anticoagulant because of its side effects’ profile and frequent 
monitoring.
Mean cost of pharmacotherapy was higher compared to other few Indian 
studies [8]. Among all drugs, 41.1% were administered parenterally 
adding a significant cost burden to patients. About 83% of total cost of 
pharmacological therapy was attributed to these parenteral drugs. It was 
found that about 64% of cost was attributed to reperfusion therapy from 
the total cost. LMWH alone accrued 48% of cost burden on patients from 
cost of reperfusion therapy. This is due to high cost of LMWH available in 
the market ranging from Rs. 409 to 579. Enoxaparin (Rs. 579) has been 
the preferred LMWH in mean dose 0.6 ml administered subcutaneously 
for a mean duration of 4 days. Fondaparinux is the least preferred in our 
study though one of the studies reported it to be cost saving alternative 
among the available LMWH [23].
Recommendations
1. Including a cost-effective alternative of enoxaparin brand available 
in the market can reduce the price burden from 48% to 32%. This 
can be properly implemented if there would have been a formulary 
guided by pharmacist and proper drug utilization studies.
2. Another strategy to overcome the price burden would be to continue 
with streptokinase followed by UFH (least cost) for the in-patients 
associated with least risk factors and no observed contraindications 
as they are under continuous monitoring in the ICU.
These recommendations may require a formulary-based intervention 
study to measure the cost burden on the patient for the management 
of ACS.
CONCLUSION
Antiplatelets were the most preferred followed by anticoagulants. 
Mean number of drugs per encounter was high but was rational as per 
standard guidelines. The mean cost for pharmacological reperfusion 
therapy was found to be more than half of mean prescription cost for 
management of ACS. LMWH (Enoxaparin) was found to accommodate 
the maximum cost of treatment per patient. Incorporating a cheaper 
cost-effective LMWH can save one-third of pharmacological cost 
and one-fourth of total prescription. Streptokinase and UFH can be 
preferred strategy to reduce the substantial cost burden of reperfusion 
therapy, until unless contraindicated.
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